Antipsychotic drugs increase N-acetylaspartate and N- acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells

Journal of Neurochemistry

Volumn 106, Issue 4, 2008, Pages 1669-1680

  Arun, Peethambaran ^a   Madhavarao, Chikkathur N ^a   Moffett, John R ^a   Namboodiri, Aryan M A ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Antipsychotics; Clozapine; Haloperidol; N acetylaspartylglutamate; N acetylaspartate; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

AMINO ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE TIME EFFECT RELATION; DRUG RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; CELL LINE, TUMOR; CLOZAPINE; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; NEUROBLASTOMA; NEURONS;

EID: 48749088364     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05524.x     Document Type: Article

References (79)

1. Abbott C. Bustillo J. (2006) What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update Curr. Opin. Psychiatry 19, 135 139.
2. Akbarian S., Huntsman M. M., Kim J. J., Tafazzoli A., Potkin S. G., Bunney Jr W. E. Jones E. G. (1995) GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cereb. Cortex 5, 550 560.
3. Arun P., Madhavarao C. N., Hershfield J. R., Moffett J. R. Namboodiri M. A. (2004) SH-SY5Y neuroblastoma cells: a model system for studying biosynthesis of NAAG. Neuroreport 15, 1167 1170.
4. Arun P., Madhavarao C. N., Moffett J. R. Namboodiri A. M. (2006) Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators. J. Neurochem. 98, 2034 2042.
5. Benes F. M. (2000) Emerging principles of altered neural circuitry in schizophrenia. Brain Res. Brain Res. Rev. 31, 251 269.
6. Berger U. V., Luthi-Carter R., Passani L. A., Elkabes S., Black I., Konradi C. Coyle J. T. (1999) Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J. Comp. Neurol. 415, 52 64.
7. Bergeron R., Coyle J. T., Tsai G. Greene R. W. (2005) NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 30, 7 16.
8. Bergeron R., Imamura Y., Frangioni J. V., Greene R. W. Coyle J. T. (2007) Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J. Neurochem. 100, 346 357.
9. Bertolino A., Nawroz S., Mattay V. S., Barnett A. S., Duyn J. H., Moonen C. T., Frank J. A., Tedeschi G. Weinberger D. R. (1996) Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 153, 1554 1563.
10. Bertolino A., Breier A., Callicott J. H., Adler C., Mattay V. S., Shapiro M., Frank J. A., Pickar D. Weinberger D. R. (2000) The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 22, 125 132.
11. Bertolino A., Callicott J. H., Mattay V. S., Weidenhammer K. M., Rakow R., Egan M. F. Weinberger D. R. (2001) The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 49, 39 46.
12. Burlina A. P., Skaper S. D., Mazza M. R., Ferrari V., Leon A. Burlina A. B. (1994) N-acetylaspartylglutamate selectively inhibits neuronal responses to N-methyl-D-aspartic acid in vitro. J. Neurochem. 63, 1174 1177.
13. Bustillo J. R., Lauriello J., Rowland L. M., Thomson L. M., Petropoulos H., Hammond R., Hart B. Brooks W. M. (2002) Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr. Res. 58, 313 321.
14. Bustillo J., Wolff C., Gutierrez A., Dettmer T. S., Cooper T. B., Allan A., Lauriello J. Valenzuela C. F. (2004) Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr. Res. 66, 31 39.
15. Bustillo J., Barrow R., Paz R., Tang J., Seraji-Bozorgzad N., Moore G. J., Bolognani F., Lauriello J., Perrone-Bizzozero N. Galloway M. P. (2006) Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 31, 751 756.
16. Bustillo J. R., Rowland L. M., Jung R., Brooks W. M., Qualls C., Hammond R., Hart B. Lauriello J. (2007) Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology [E-pub ahead of print] doi :.
17. Callicott J. H., Bertolino A., Egan M. F., Mattay V. S., Langheim F. J. Weinberger D. R. (2000a) Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 157, 1646 1651.
18. Callicott J. H., Bertolino A., Mattay V. S., Langheim F. J., Duyn J., Coppola R., Goldberg T. E. Weinberger D. R. (2000b) Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 10, 1078 1092.
19. Chen L. J., Gao Y. Q., Li X. J., Shen D. H. Sun F. Y. (2005) Melatonin protects against MPTP/MPP+ -induced mitochondrial DNA oxidative damage in vivo and in vitro. J. Pineal Res. 39, 34 42.
20. Deicken R. F., Johnson C. Pegues M. (2000) Proton magnetic resonance spectroscopy of the human brain in schizophrenia. Rev. Neurosci. 11, 147 158.
21. Deutch A. Y., Moghaddam B., Innis R. B., Krystal J. H., Aghajanian G. K., Bunney B. S. Charney D. S. (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr. Res. 4, 121 156.
22. Dixon L. B., Lehman A. F. Levine J. (1995) Conventional antipsychotic medications for schizophrenia. Schizophr. Bull. 21, 567 577.
23. Dziedzicka-Wasylewska M. Solich J. (2004) Neuronal cell lines transfected with the dopamine D2 receptor gene promoter as a model for studying the effects of antidepressant drugs. Brain Res. Mol. Brain Res. 128, 75 82.
24. Fang J., Zuo D. Yu P. H. (1995) Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl) 121, 373 378.
25. Fannon D., Simmons A., Tennakoon L., O'Ceallaigh S., Sumich A., Doku V., Shew C. Sharma T. (2003) Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol. Psychiatry 54, 587 598.
26. Farde L., Wiesel F. A., Nordstrom A. L. Sedvall G. (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 99 (Suppl S28 S31.
27. Faull K. F., Rafie R., Pascoe N., Marsh L. Pfefferbaum A. (1999) N-acetylaspartic acid (NAA) and N-acetylaspartylglutamic acid (NAAG) in human ventricular, subarachnoid, and lumbar cerebrospinal fluid. Neurochem. Res. 24, 1249 1261.
28. Flores C. Coyle J. T. (2003) Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology 28, 1227 1234.
29. Flynn S. W., Lang D. J., Mackay A. L. et al. (2003) Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol. Psychiatry 8, 811 820.
30. Galli T., Godeheu G., Artaud F., Desce J. M., Pittaluga A., Barbeito L., Glowinski J. Chëramy A. (1991) Specific role of N-acetyl-aspartyl-glutamate in the in vivo regulation of dopamine release from dendrites and nerve terminals of nigrostriatal dopaminergic neurons in the cat. Neuroscience 42, 19 28.
31. Goghari V. M., Lang D. J., Flynn S. W., Mackay A. L. Honer W. G. (2005) Smaller corpus callosum subregions containing motor fibers in schizophrenia. Schizophr. Res. 73, 59 68.
32. Hakak Y., Walker J. R., Li C., Wong W. H., Davis K. L., Buxbaum J. D., Haroutunian V. Fienberg A. A. (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl Acad. Sci. USA 98, 4746 4751.
33. Harte M. K., Bachus S. B. Reynolds G. P. (2005) Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr. Res. 75, 303 308.
34. Hashimoto T., Arion D., Unger T., Maldonado-Aviles J. G., Morris H. M., Volk D. W., Mirnics K. Lewis D. A. (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 13, 147 161.
35. Heimberg C., Komoroski R. A., Lawson W. B., Cardwell D. Karson C. N. (1998) Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res. 83, 105 115.
36. Javitt D. C. (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9, 984 997.
37. Javitt D. C. Coyle J. T. (2004) Decoding schizophrenia. Sci. Am. 290, 48 55.
38. Konopaske G. T., Dorph-Petersen K. A., Sweet R. A., Pierri J. N., Zhang W., Sampson A. R. Lewis D. A. (2008) Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol. Psychiatry 63, 759 765.
39. Ledeen R. W., Wang J., Wu G., Lu Z. H., Chakraborty G., Meyenhofer M., Tyring S. K. Matalon R. (2006) Physiological role of N-acetylaspartate: contribution to myelinogenesis, in N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System, Vol. 576 (Moffett J. R., Tieman S. B., Weinberger D. R., Coyle J. T. Namboodiri M. A. eds pp. 131 143. Springer Science + Business Media, New York, NY.
40. Lewis D. A. (2000) GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res. Brain Res. Rev. 31, 270 276.
41. Lindquist D. M., Hawk R. M., Karson C. N. Komoroski R. A. (2000) Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn. Reson. Med. 43, 355 358.
42. Losi G., Vicini S. Neale J. (2004) NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. Neuropharmacology 46, 490 496.
43. Ma D., Zhang J., Sugahara K., Ageta T., Nakayama K. Kodama H. (1999) Simultaneous determination of N-acetylaspartic acid, N-acetylglutamic acid, and N-acetylaspartylglutamic acid in whole brain of 3- mercaptopropionic acid-treated rats using liquid chromatography- atmospheric pressure chemical ionization mass spectrometry. Anal. Biochem. 276, 124 128.
44. Madhavarao C. N., Arun P., Moffett J. R. et al. (2005) Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc. Natl Acad. Sci. USA 102, 5221 5226.
45. Marenco S., Bertolino A. Weinberger D. R. (2006) In vivo NMR measures of NAA and the neurobiology of schizophrenia, in N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System, Vol. 576 (Moffett J. R., Tieman S. B., Weinberger D. R., Coyle J. T. Namboodiri M. A., eds pp. 227 240. Springer Science + Business Media, New York, NY.
46. Mateo Z. Porter J. T. (2007) Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex. Neurosci. 146, 1062 1072.
47. Mathew R., Arun P., Madhavarao C., Moffett J. Namboodiri A. (2005) Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate levels in brain. J. Pharmacol. Exp. Ther. 315, 297 303.
48. McEvoy J. P. (1983) The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J. Clin. Psychopharmacol. 3, 288 302.
49. McMillan C. R., Sharma R., Ottenhof T. Niles L. P. (2007) Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci. Lett. 419, 202 206.
50. Moffett J. R. (2003) Reductions in N-acetylaspartylglutamate and the 67 kDa form of glutamic acid decarboxylase immunoreactivities in the visual system of albino and pigmented rats after optic nerve transections. J. Comp. Neurol. 458, 221 239.
51. Moffett J. R. Namboodiri M. A. (1995) Differential distribution of N-acetylaspartylglutamate and N- acetylaspartate immunoreactivities in rat forebrain. J. Neurocytol. 24, 409 433.
52. Moffett J. R. Namboodiri M. A. (2006) Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system, in N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System, Vol. 576 (Moffett J. R., Tieman S. B., Weinberger D. R., Coyle J. T. Namboodiri M. A. eds pp. 7 26. Springer Science + Business Media, New York, NY.
53. Moffett J. R., Ross B., Arun P., Madhavarao C. N. Namboodiri A. M. (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81, 89 131.
54. Moghaddam B. Adams B. W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349 1352.
55. Nudmamud S., Reynolds L. M. Reynolds G. P. (2003) N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biol. Psychiatry 53, 1138 1141.
56. Ohrmann P., Siegmund A., Suslow T., Pedersen A., Spitzberg K., Kersting A., Rothermundt M., Arolt V., Heindel W. Pfleiderer B. (2006) Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatr. Res. 41, 625 634.
57. Okumura N., Otsuki S. Nasu H. (1959) The influence of insulin hypoglycaemic coma, repeated electroshocks and chlorpromazine or beta-phenylisopropylmethylamine administration on the free amino acids in the brain. J. Biochem. (Tokyo) 46, 247 252.
58. Olszewski R. T., Bukhari N., Zhou J. et al. (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J. Neurochem. 89, 876 885.
59. Olszewski R. T., Wegorzewska M. M., Monteiro A. C., Krolikowski K. A., Zhou J., Kozikowski A. P., Long K., Mastropaolo J., Deutsch S. I. Neale J. H. (2007) Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol. Psychiatry 63, 86 91.
60. Patil S. T., Zhang L., Martenyi F. et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13, 1102 1107.
61. Presgraves S. P., Ahmed T., Borwege S. Joyce J. N. (2004) Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 5, 579 598.
62. Rigotti D. J., Inglese M., Babb J. S., Rovaris M., Benedetti B., Filippi M., Grossman R. I. Gonen O. (2007) Serial whole-brain N-acetylaspartate concentration in healthy young adults. AJNR Am. J. Neuroradiol. 28, 1650 1651.
63. Sacha P., Zamecnik J., Barinka C., Hlouchova K., Vicha A., Mlcochova P., Hilgert I., Eckschlager T. Konvalinka J. (2007) Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144, 1361 1372.
64. Seeman P., Lee T., Chau-Wong M. Wong K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717 719.
65. Slusher B. S., Vornov J. J., Thomas A. G. et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5, 1396 1402.
66. Steen R. G., Hamer R. M. Lieberman J. A. (2005) Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30, 1949 1962.
67. Tanaka Y., Obata T., Sassa T., Yoshitome E., Asai Y., Ikehira H., Suhara T., Okubo Y. Nishikawa T. (2006) Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction. Psychiatry Clin. Neurosci. 60, 365 372.
68. Thomas A. G., Vornov J. J., Olkowski J. L., Merion A. T. Slusher B. S. (2000) N-Acetylated alpha-linked acidic dipeptidase converts N- acetylaspartylglutamate from a neuroprotectant to a neurotoxin. J. Pharmacol. Exp. Ther. 295, 16 22.
69. Tkachev D., Mimmack M. L., Ryan M. M., Wayland M., Freeman T., Jones P. B., Starkey M., Webster M. J., Yolken R. H. Bahn S. (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362, 798 805.
70. Tkachev D., Mimmack M. L., Huffaker S. J., Ryan M. Bahn S. (2007) Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int. J. Neuropsychopharmacol. 10, 557 563.
71. Tsai S. J. (2005) Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med. Sci. Monit. 11, HY39 HY45.
72. Tsai G. Coyle J. T. (2002) Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42, 165 179.
73. Tsai G., Passani L. A., Slusher B. S., Carter R., Baer L., Kleinman J. E. Coyle J. T. (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52, 829 836.
74. Westbrook G. L., Mayer M. L., Namboodiri M. A. Neale J. H. (1986) High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J. Neurosci. 6, 3385 3392.
75. Wroblewska B., Wroblewski J. T., Pshenichkin S., Surin A., Sullivan S. E. Neale J. H. (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 69, 174 181.
76. Xi Z. X., Baker D. A., Shen H., Carson D. S. Kalivas P. W. (2002) Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J. Pharmacol. Exp. Ther. 300, 162 171.
77. Zhao J., Ramadan E., Cappiello M., Wroblewska B., Bzdega T. Neale J. H. (2001) NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. Eur. J. Neurosci. 13, 340 346.
78. Zhong C., Zhao X., Van K. C. et al. (2006) NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J. Neurochem. 97, 1015 1025.
79. Zhou J., Neale J. H., Pomper M. G. Kozikowski A. P. (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov. 4, 1015 1026.